Abstract Library

#4185 Primary hepatic neuroendocrine neoplasms – Clinical characteristics and treatment outcomes of a rare disease

Introduction: Liver involvement in Neuroendocrine Neoplasms (NEN) most commonly encompasses metastases from other organs or from an unknown primary. The current WHO classification defines primary hepatic NEN (PHNEN) as a distinct entity. With only few cases of PHNEN reported and difficulty to discern them from hepatic metastases, evidence on optimal management is very limited.

Conference:

Presenting Author:

Authors: Apostolidis L, Kender Z, Flegka V, Winkler E, Krug S,

Keywords: hepatic NEN, liver NEN, PHNEN,

#3648 Treatment preferences for somatostatin analogues in neuroendocrine tumors (NETs) among patients, clinicians and nurses in Australia

Introduction: Long-acting somatostatin analogues (LA SSAs) are commonly used as first-line treatment in low-grade pancreatic or midgut neuroendocrine tumors (NETs). Due to the long-term nature of treatment, treatment preferences should be taken into consideration. Funding for this study was provided by Ipsen.

Conference:

Presenting Author:

Authors: Cummins M, Fifer S, Winkler K, Cherian H,

Keywords: Treatment preferences, LA SSAs, NET,

#3080 Impact of Multimodal Perioperative Treatment in Patients with Resected Non-Metastatic Grade 3 Neuroendocrine Neoplasms (NEN G3)

Introduction: Patients with grade 3 neuroendocrine neoplasm (NEN G3) have a limited prognosis. Even in a non-metastatic stage, the risk of recurrence after surgery is high. Multimodal perioperative treatment, including chemotherapy and/or radiotherapy in an adjuvant or neoadjuvant setting, has improved the prognosis in numerous tumor entities; however, it has not been systematically evaluated in NEN G3 so far. Nevertheless, perioperative chemotherapy is generally recommended in most current treatment guidelines for NEN G3.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Apostolidis L, Starke H, Bhatti I, Jäger D, Winkler E,

Keywords: NEN G3, neuroendocrine carcinoma, adjuvant, neoadjuvant, surgery,

#2265 Activity of Bevacizumab in Neuroendocrine Neoplasms

Introduction: The combination of the anti-VEGF antibody bevacizumab (BEV) with a multitude of other antineoplastic substances has shown promising activity in neuroendocrine neoplasms (NEN). However, data proving the superiority of BEV-containing vs. BEV-free protocols are lacking.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Apostolidis L

Authors: Fejzibegovic N, Jäger D, Winkler E, Apostolidis L,

Keywords: neuroendocrine neoplasm, targeted therapy, bevacizumab, antiangiogenesis,

#2259 Clinical Characteristics, Treatment Outcomes and Potential Novel Therapeutic Options for Patients with Prostatic Neuroendocrine Carcinoma

Introduction: Prostatic neuroendocrine carcinomas (PNECs) are rare tumors with poor prognosis. While platinum and etoposide based chemotherapy regimens (PE) are commonly applied in first-line for advanced disease, clinical-grade evidence for treatment options in second-line and beyond is very limited.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Apostolidis L, Nientiedt C, Winkler E, Stenzinger A, Duensing S,

Keywords: neuroendocrine carcinoma, prostate, chemotherapy, immunotherapy,